WO2001077167A3 - Methods of investigating, diagnosing, and treating amyloidosis - Google Patents
Methods of investigating, diagnosing, and treating amyloidosis Download PDFInfo
- Publication number
- WO2001077167A3 WO2001077167A3 PCT/US2001/011043 US0111043W WO0177167A3 WO 2001077167 A3 WO2001077167 A3 WO 2001077167A3 US 0111043 W US0111043 W US 0111043W WO 0177167 A3 WO0177167 A3 WO 0177167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amyloidosis
- amyloid
- present
- provides
- investigating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001253158A AU2001253158A1 (en) | 2000-04-05 | 2001-04-05 | Methods of investigating, diagnosing, and treating amyloidosis |
CA2404237A CA2404237C (en) | 2000-04-05 | 2001-04-05 | Methods of investigating, diagnosing, and treating amyloidosis |
EP01926636A EP1353944A2 (en) | 2000-04-05 | 2001-04-05 | Methods of investigating, diagnosing, and treating amyloidosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19468400P | 2000-04-05 | 2000-04-05 | |
US60/194,684 | 2000-04-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001077167A2 WO2001077167A2 (en) | 2001-10-18 |
WO2001077167A3 true WO2001077167A3 (en) | 2003-08-28 |
Family
ID=22718526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011043 WO2001077167A2 (en) | 2000-04-05 | 2001-04-05 | Methods of investigating, diagnosing, and treating amyloidosis |
Country Status (5)
Country | Link |
---|---|
US (1) | US7485616B2 (en) |
EP (1) | EP1353944A2 (en) |
AU (1) | AU2001253158A1 (en) |
CA (1) | CA2404237C (en) |
WO (1) | WO2001077167A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7485616B2 (en) * | 2000-04-05 | 2009-02-03 | University Of Tennessee Research Foundation | Methods of investigating, diagnosing, and treating amyloidosis |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
TWI355389B (en) * | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
PE20061329A1 (en) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
JP2009512644A (en) * | 2005-10-17 | 2009-03-26 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Methods and materials for generating a general anti-amyloid immune response in mammals |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
ES2498040T3 (en) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanized anti-beta antibodies |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
CN102016059B (en) | 2007-12-28 | 2014-10-22 | 依兰制药公司 | Treatment and prophylaxis of amyloidosis |
FI20085340L (en) * | 2008-04-22 | 2009-10-23 | Medixine Oy | Health screening and a method for implementing the health screening |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2017184973A1 (en) * | 2016-04-22 | 2017-10-26 | University Of Tennessee Research Foundation | Identifying amyloidogenic proteins & amyloidogenic risk |
CA3077361A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JOP20200132A1 (en) | 2017-11-29 | 2022-10-30 | Prothena Biosciences Ltd [Ie/Ie] | Lyophilized formulation of a monoclonal antibody against transthyretin |
WO2021168156A1 (en) * | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016819A1 (en) * | 1990-04-27 | 1991-11-14 | Molecular Rx., Inc. | Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein |
WO1995012815A1 (en) * | 1993-11-04 | 1995-05-11 | The Research Foundation Of State University Of New York | METHOD OF PREVENTING AGGREGATION OF AMYLOID β-PROTEIN |
WO1995031996A1 (en) * | 1994-05-25 | 1995-11-30 | Milkhaus Lab | Materials and methods for treatment of plaquing diseases |
WO1999027944A1 (en) * | 1997-12-02 | 1999-06-10 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO2000072876A2 (en) * | 1999-06-01 | 2000-12-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3521684A1 (en) * | 1985-06-18 | 1986-12-18 | Dr. Müller-Lierheim KG, Biologische Laboratorien, 8033 Planegg | METHOD FOR COATING POLYMERS |
JP2988635B2 (en) * | 1990-09-18 | 1999-12-13 | 塩野義製薬株式会社 | Monoclonal antibody against human IgE |
AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
CN1344275A (en) | 1998-05-21 | 2002-04-10 | 田纳西州立大学研究股份有限公司 | Methods for amyloid removal using anti-amyloid antibodies |
US7485616B2 (en) * | 2000-04-05 | 2009-02-03 | University Of Tennessee Research Foundation | Methods of investigating, diagnosing, and treating amyloidosis |
-
2001
- 2001-04-05 US US09/825,872 patent/US7485616B2/en not_active Expired - Fee Related
- 2001-04-05 EP EP01926636A patent/EP1353944A2/en not_active Withdrawn
- 2001-04-05 WO PCT/US2001/011043 patent/WO2001077167A2/en active Application Filing
- 2001-04-05 CA CA2404237A patent/CA2404237C/en not_active Expired - Fee Related
- 2001-04-05 AU AU2001253158A patent/AU2001253158A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016819A1 (en) * | 1990-04-27 | 1991-11-14 | Molecular Rx., Inc. | Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein |
WO1995012815A1 (en) * | 1993-11-04 | 1995-05-11 | The Research Foundation Of State University Of New York | METHOD OF PREVENTING AGGREGATION OF AMYLOID β-PROTEIN |
WO1995031996A1 (en) * | 1994-05-25 | 1995-11-30 | Milkhaus Lab | Materials and methods for treatment of plaquing diseases |
WO1999027944A1 (en) * | 1997-12-02 | 1999-06-10 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
WO2000072876A2 (en) * | 1999-06-01 | 2000-12-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
Non-Patent Citations (2)
Title |
---|
HELMUTH ET AL: "Further progress on a beta -amyloid vaccine", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 289, no. 5478, 21 July 2000 (2000-07-21), pages 349 - 496, XP002154517, ISSN: 0036-8075 * |
SCHENK D ET AL: "Immunization with amyloid-beta attenuates Alzheimer -disease-like pathology in the PDAPP mouse [see comments]", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 400, no. 6740, 8 July 1999 (1999-07-08), pages 173 - 177, XP002154168, ISSN: 0028-0836 * |
Also Published As
Publication number | Publication date |
---|---|
US7485616B2 (en) | 2009-02-03 |
CA2404237C (en) | 2010-01-26 |
US20020019335A1 (en) | 2002-02-14 |
AU2001253158A1 (en) | 2001-10-23 |
CA2404237A1 (en) | 2001-10-18 |
EP1353944A2 (en) | 2003-10-22 |
WO2001077167A2 (en) | 2001-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001077167A3 (en) | Methods of investigating, diagnosing, and treating amyloidosis | |
DE60329165D1 (en) | DETECTION AND / OR OBSERVATION OF SYNUCLEIN ASSOCIATED DISEASES | |
DE60112744T2 (en) | DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF MORBUS CROHN THROUGH THE USE OF OMPC ANTIGEN | |
EA200602015A1 (en) | HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE | |
HK1117083A1 (en) | Compositions and methods for treatment of eye disorders | |
ATE350060T1 (en) | AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT | |
ATE438716T1 (en) | USE OF PROTEIN KINASES TO DIAGNOSE AND TREAT ALZHEIMER'S DISEASE | |
DE69726195D1 (en) | DEVICE FOR DIAGNOSIS AND TREATMENT OF ARRHYTMS | |
ATE526041T1 (en) | METHOD FOR INHIBITING OCCULAR PROCESSES | |
EA200401170A1 (en) | HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE | |
DE602004010381D1 (en) | METHOD AND DEVICE FOR TREATING WATER FOR INJECTION DRILLING | |
ATE310955T1 (en) | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CHEMOKINE RECEPTOR-RELATED DISEASES | |
ATE320803T1 (en) | METHOD FOR TREATING ALZHEIMER'S DISEASE | |
WO2003007803A3 (en) | Methods for diagnosing and treating alzheimer's disease and parkinson's disease | |
DE60102533D1 (en) | Method and device for the statistical analysis of QT time intervals as a function of the RR time interval changes | |
ATE545658T1 (en) | METHOD FOR TREATING SYNOVIAL SARCOMA | |
ATE338142T1 (en) | METHODS OF DIAGNOSIS AND TREATMENT OF HEART DISEASE | |
WO2005060542A3 (en) | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents | |
DE602004031024D1 (en) | THE IDENTIFICATION OF POLYNUCLEOTIDES OF PORPHYROMONAS GINGIVALIS VIRULENT FOR DIAGNOSIS, TREATMENT AND OBSERVATION OF PERIODONTAL DISEASES | |
DE69940024D1 (en) | METHOD FOR SCREENING ANTI-AMYLOIDOGENIC PROPERTIES AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
ATE422671T1 (en) | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | |
EP1701611A4 (en) | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar | |
DE602004026683D1 (en) | METHOD FOR DIAGNOSIS AND MONITORING OF NEUROLOGICAL ILLNESSES BY DETECTION OF ENCEPHALOTOXIN | |
WO2004016751A3 (en) | Methods of treating neurodegenerative diseases | |
WO2006122035A3 (en) | Method for treating central pain syndrome or for inducing centrally generated pain in an animal model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2404237 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001926636 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001926636 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |